Shang Hai Zheng Quan Bao·2026-01-22 18:55Group 1 - The fund being discussed is the Morgan Hang Seng Biotechnology Exchange-Traded Fund (ETF), which is a type of open-ended index securities investment fund [1][2][25]. - The fund's initial offering price is set at RMB 1.00 per share, and the subscription period is from January 26, 2026, to February 6, 2026 [3][5][29]. - The maximum fundraising limit for the fund is RMB 2 billion, and if this limit is reached, the fundraising will close early [5][6]. Group 2 - The fund is managed by JPMorgan Asset Management (China) Limited, with Guosen Securities Co., Ltd. serving as the custodian [2][26][55]. - The fund targets individual investors, institutional investors, qualified foreign investors, and other investors permitted by laws and regulations [2][23]. - The fund aims to passively track the performance of the Hang Seng Biotechnology Index, which reflects the overall performance of the largest 30 biotechnology companies listed in Hong Kong [9][10][24]. Group 3 - Investors can subscribe to the fund through online cash subscription or offline cash subscription methods [7][32]. - The fund's subscription fees are structured such that there are no fees for offline cash subscriptions, while online subscriptions may incur a fee of up to 0.3% [33][34]. - Investors must have a securities account to participate in the fund's subscription, specifically an A-share account or a fund account [37][38].